Jianjin Xu

7PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersMolecular targetsPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Large and complex data theory
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 03, 2026
Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.

Michael S Leapman, Jessica B Long, Sarah Westvold

|Aug 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.

Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng

|Mar 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Jaleh Fallah, Jianjin Xu, Chana Weinstock

|Dec 21, 2023
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Jaleh Fallah, Jianjin Xu, Chana Weinstock

|Sep 14, 2021
Dynamic borrowing from a single prior data source using the conditional power prior.

Laura Thompson, Jianxiong Chu, Jianjin Xu

|Jun 13, 2020
Likelihood Ratio Test Method for Multiple Medical Devices Comparison Using Multiple-Site Data with Continuous Outcomes.

Tingting Hu, Jianjin Xu, Lan Huang

Pageof 2

Frequent Collaborators

4 joint publications

Jaleh Fallah

3 joint publications

Laleh Amiri-Kordestani

3 joint publications

Richard Pazdur

2 joint publications

Elaine Chang